A Phase 3 interventional study of Nivolumab and Ipilimumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 290 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 9 that started in 2015, is one of 24 in phase 3, and was the 21st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,747 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 62 that completed or were terminated, 44 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one has the largest enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2015, is one of 27 in phase 3, and was the 44th registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab intravenously (IV) as specified
Drug: Nivolumab
Nivolumab + Ipilimumab IV as specified
Drug: Nivolumab · Drug: Ipilimumab
Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
Drug: Nivolumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Pemetrexed · Drug: Paclitaxel
Chemotherapy administered on specified days of IV chemotherapy
Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Pemetrexed · Drug: Paclitaxel
Also known as: Opdivo
Also known as: Yervoy
Progression-Free Survival Per BICR
Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
Overall Survival
OS for all randomized participants is the time between randomization date and the date of death from any cause.
Time frame: From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)
Objective Response Rate (ORR) Per BICR
Objective response rate (ORR) is defined as the number of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
Percentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Disease-Related Symptom Deterioration by Week 12 defined as a 10 points or more increase from baseline in LCSS average score at any time (on or off-treatment) up to 95 days from randomization date.
Time frame: Week 12
| Milestone | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 396 | 396 | 397 | 187 | 177 | 186 | 377 | 378 | 126 | 127 |
| Completed | 391 | 391 | 387 | 185 | 172 | 183 | 375 | 371 | 126 | 123 |
| Not completed | 5 | 5 | 10 | 2 | 5 | 3 | 2 | 7 | 0 | 4 |
| Withdrew: Adverse events unrelated to study drug | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 5 | 0 | 0 |
| Withdrew: Other reasons | 4 | 1 | 4 | 1 | 4 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Subject no longer meets study criteria | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Subject withdrew consent | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 1 | 0 | 3 |
| Withdrew: Subject request to discontinue study treatment | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 391 | 391 | 387 | 185 | 172 | 183 | 375 | 371 | 126 | 123 |
| Completed | 45 | 37 | 94 | 14 | 20 | 32 | 40 | 83 | 0 | 37 |
| Not completed | 346 | 354 | 293 | 171 | 152 | 151 | 335 | 288 | 126 | 86 |
| Withdrew: Not reported | 8 | 6 | 4 | 4 | 2 | 1 | 14 | 8 | 5 | 2 |
| Withdrew: Other reasons | 5 | 6 | 12 | 7 | 5 | 1 | 8 | 8 | 21 | 1 |
| Withdrew: Administrative reason by sponsor | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant meet no longer study criteria | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Poor/non compliance | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Maximum clinical benefit | 3 | 3 | 1 | 1 | 3 | 0 | 3 | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Participant withdrew consent | 5 | 5 | 3 | 3 | 1 | 3 | 3 | 3 | 2 | 3 |
| Withdrew: Participant request to discontinue treatment | 5 | 3 | 15 | 5 | 3 | 6 | 13 | 15 | 4 | 18 |
| Withdrew: Adverse event unrelated to study drug | 23 | 29 | 22 | 18 | 11 | 15 | 25 | 19 | 4 | 2 |
| Withdrew: Death | 4 | 7 | 0 | 0 | 1 | 2 | 6 | 5 | 9 | 0 |
| Withdrew: Study drug toxicity | 79 | 51 | 31 | 39 | 12 | 25 | 52 | 30 | 20 | 9 |
| Withdrew: Disease progression | 212 | 240 | 202 | 93 | 113 | 96 | 208 | 195 | 59 | 46 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival Per BICR | 5.06 (4.07 to 6.31) | 4.17 (3.22 to 5.32) | 5.55 (4.63 to 5.82) | 4.90 (3.15 to 6.28) | 5.55 (4.63 to 6.90) | 4.70 (4.21 to 5.59) | 8.34 (7.10 to 9.59) | 5.52 (4.47 to 5.85) | 5.78 (4.14 to 8.34) | 5.49 (4.37 to 6.77) |
OS for all randomized participants is the time between randomization date and the date of death from any cause.
| months | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival | 17.12 (14.95 to 20.17) | 15.70 (13.27 to 18.14) | 14.88 (12.71 to 16.72) | 17.45 (13.21 to 22.05) | 15.21 (12.29 to 19.78) | 12.19 (9.17 to 14.32) | 18.27 (15.84 to 21.65) | 14.72 (12.42 to 16.79) | 20.99 (16.95 to 25.17) | 15.11 (13.17 to 18.89) |
Objective response rate (ORR) is defined as the number of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Per BICR | 36.4 (31.6 to 41.3) | 27.5 (23.2 to 32.2) | 29.7 (25.3 to 34.5) | 26.2 (20.1 to 33.1) | 37.9 (30.7 to 45.4) | 23.1 (17.3 to 29.8) | 52.3 (47.1 to 57.4) | 29.9 (25.3 to 34.8) | 38.1 (29.6 to 47.2) | 30.7 (22.8 to 39.5) |
The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Disease-Related Symptom Deterioration by Week 12 defined as a 10 points or more increase from baseline in LCSS average score at any time (on or off-treatment) up to 95 days from randomization date.
| percentage of participants | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale | 31.3 (26.8 to 36.1) | 35.4 (30.6 to 40.3) | 25.7 (21.5 to 30.3) | 33.2 (26.5 to 40.4) | 28.8 (22.3 to 36.1) | 37.6 (30.7 to 45.0) | 30.0 (25.4 to 34.9) | 24.3 (20.1 to 29.0) | 23.0 (16.0 to 31.4) | 26.0 (18.6 to 34.5) |
Collected over Serious and non-serious adverse events were collected from first dose (Day 1) and 30 days after last dose of study therapy (up to approximately 105 months) and all cause mortality was collected from Day 1 and up to 481 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1-Arm B: Nivo + Ipi | 316/391 (80.8%) | 275/391 (70.3%) | 366/391 (93.6%) |
| Part 1-Arm A: Nivolumab | 333/391 (85.2%) | 239/391 (61.1%) | 356/391 (91%) |
| Part 1-Arm C: Chemotherapy | 339/387 (87.6%) | 213/387 (55%) | 361/387 (93.3%) |
| Part 1-Arm D: Nivo + Ipi | 159/185 (85.9%) | 128/185 (69.2%) | 172/185 (93%) |
| Part 1-Arm G: Nivo + Chemo | 157/172 (91.3%) | 112/172 (65.1%) | 167/172 (97.1%) |
| Part 1-Arm F: Chemotherapy | 174/183 (95.1%) | 91/183 (49.7%) | 165/183 (90.2%) |
| Part 2 - Arm H: Nivolumab + Chemotherapy | 314/375 (83.7%) | 240/375 (64%) | 357/375 (95.2%) |
| Part 2 - Arm I: Chemotherapy | 335/371 (90.3%) | 180/371 (48.5%) | 345/371 (93%) |
| Part 3 -Arm J: Nivolumab + Ipilimumab | 95/126 (75.4%) | 78/126 (61.9%) | 124/126 (98.4%) |
| Part 3 - Arm K: Chemotherapy | 94/123 (76.4%) | 60/123 (48.8%) | 121/123 (98.4%) |
| Event | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 98/391 | 102/391 | 87/387 | 39/185 | 48/172 | 41/183 | 81/375 | 78/371 | 18/126 | 9/123 |
| PneumoniaInfections and infestations | 40/391 | 29/391 | 31/387 | 18/185 | 15/172 | 8/183 | 34/375 | 29/371 | 11/126 | 8/123 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 20/391 | 11/391 | 4/387 | 7/185 | 5/172 | 1/183 | 14/375 | 1/371 | 11/126 | 0/123 |
| Platelet count decreasedInvestigations | 0/391 | 0/391 | 3/387 | 0/185 | 0/172 | 1/183 | 6/375 | 2/371 | 3/126 | 8/123 |
| AnaemiaBlood and lymphatic system disorders | 4/391 | 4/391 | 9/387 | 4/185 | 10/172 | 8/183 | 14/375 | 10/371 | 1/126 | 2/123 |
| MyelosuppressionBlood and lymphatic system disorders | 0/391 | 0/391 | 0/387 | 0/185 | 0/172 | 0/183 | 1/375 | 1/371 | 0/126 | 7/123 |
| Immune-mediated hepatitisHepatobiliary disorders | 3/391 | 0/391 | 0/387 | 0/185 | 0/172 | 0/183 | 1/375 | 0/371 | 7/126 | 0/123 |
| DiarrhoeaGastrointestinal disorders | 6/391 | 3/391 | 4/387 | 9/185 | 1/172 | 3/183 | 6/375 | 2/371 | 4/126 | 2/123 |
| PyrexiaGeneral disorders | 5/391 | 5/391 | 5/387 | 3/185 | 3/172 | 3/183 | 6/375 | 5/371 | 6/126 | 0/123 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/391 | 3/391 | 9/387 | 2/185 | 4/172 | 7/183 | 16/375 | 6/371 | 0/126 | 0/123 |
| Event | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 47/391 | 51/391 | 159/387 | 25/185 | 80/172 | 76/183 | 174/375 | 151/371 | 63/126 | 93/123 |
| White blood cell count decreasedInvestigations | 8/391 | 5/391 | 19/387 | 1/185 | 17/172 | 6/183 | 41/375 | 39/371 | 22/126 | 59/123 |
| NauseaGastrointestinal disorders | 93/391 | 81/391 | 174/387 | 41/185 | 79/172 | 74/183 | 126/375 | 133/371 | 17/126 | 30/123 |
| Neutrophil count decreasedInvestigations | 9/391 | 11/391 | 50/387 | 2/185 | 31/172 | 20/183 | 52/375 | 54/371 | 16/126 | 54/123 |
| Platelet count decreasedInvestigations | 6/391 | 10/391 | 31/387 | 2/185 | 22/172 | 25/183 | 38/375 | 30/371 | 22/126 | 49/123 |
| HyponatraemiaMetabolism and nutrition disorders | 39/391 | 17/391 | 20/387 | 14/185 | 11/172 | 8/183 | 25/375 | 16/371 | 47/126 | 18/123 |
| ConstipationGastrointestinal disorders | 78/391 | 70/391 | 104/387 | 36/185 | 63/172 | 53/183 | 84/375 | 83/371 | 20/126 | 25/123 |
| Aspartate aminotransferase increasedInvestigations | 47/391 | 37/391 | 21/387 | 27/185 | 16/172 | 12/183 | 48/375 | 25/371 | 46/126 | 32/123 |
| Decreased appetiteMetabolism and nutrition disorders | 130/391 | 97/391 | 109/387 | 61/185 | 61/172 | 52/183 | 105/375 | 88/371 | 40/126 | 34/123 |
| Weight decreasedInvestigations | 37/391 | 20/391 | 22/387 | 17/185 | 14/172 | 8/183 | 32/375 | 31/371 | 44/126 | 19/123 |
| Age, Customized(Participants) | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 65 | 199 | 210 | 207 | 107 | 91 | 98 | 214 | 196 | 82 | 84 | 1488 |
| =>65 | 197 | 186 | 190 | 80 | 86 | 88 | 163 | 182 | 44 | 43 | 1259 |
| Sex: Female, Male(Participants) | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 141 | 124 | 137 | 49 | 47 | 61 | 113 | 115 | 18 | 20 | 825 |
| Male | 255 | 272 | 260 | 138 | 130 | 125 | 264 | 263 | 108 | 107 | 1922 |
| Race/Ethnicity, Customized(Participants) | Part 1-Arm B: Nivo + Ipi | Part 1-Arm A: Nivolumab | Part 1-Arm C: Chemotherapy | Part 1-Arm D: Nivo + Ipi | Part 1-Arm G: Nivo + Chemo | Part 1-Arm F: Chemotherapy | Part 2 - Arm H: Nivolumab + Chemotherapy | Part 2 - Arm I: Chemotherapy | Part 3 -Arm J: Nivolumab + Ipilimumab | Part 3 - Arm K: Chemotherapy | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 299 | 317 | 305 | 143 | 136 | 133 | 272 | 266 | 0 | 0 | 1871 |
| Black | 4 | 6 | 5 | 0 | 2 | 2 | 1 | 3 | 0 | 0 | 23 |
| Asian | 84 | 67 | 82 | 41 | 38 | 45 | 93 | 94 | 126 | 127 | 797 |
| Other | 5 | 6 | 3 | 1 | 1 | 5 | 8 | 12 | 0 | 0 | 41 |
| American Indian or Alaska Native | 4 | 0 | 2 | 2 | 0 | 1 | 3 | 1 | 0 | 0 | 13 |
| Native Hawaiian or other pacific islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Showing the first 100 of 290 sites across 33 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Oct 2024, 110 months.
Results were first posted in Oct 2025, 1 year after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 110 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab · Carboplatin · Cisplatin · Gemcitabine · Pemetrexed · Paclitaxel
Carcinoma, Non-Small-Cell Lung →